Compare Charles River Laboratories Intl. Inc (CRL) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Icl Group Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Icl Group Ltd trades at $5.03 (market cap $6.47B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.2× Icl Group Ltd's market cap, and Icl Group Ltd pays a 4.11% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Icl Group Ltd for 56 Days on average.
| CRL | ICL | |
|---|---|---|
Market Cap | $14.23B | $6.47B |
Volume | 1,176,885 | 1,387,140 |
Sector | Health | Basic Materials |
52-Week High | $310.77 | $6.84 |
52-Week Low | $149.93 | $4.80 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $17.06B | $9.11B |
Dividend Yield | — | 4.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
ICL Group trades at $5.015, down 1.28% today, with a bearish technical outlook despite recent earnings beats. The company maintains stable cash flow generation with $1.06B from operations in 2025, though revenue has declined from $10.0B in 2022 to $7.15B in 2025. Recent Q2 2026 results showed earnings of $0.12 per share, beating estimates, and the company announced a dividend of $0.06 payable September 16, 2026.
While ICL shows fundamental stability with reasonable valuation metrics (P/E 20.83, P/S 0.84), the stock faces headwinds from declining profitability margins and bearish technical signals. Analyst consensus remains neutral with 100% hold ratings, though the $6.08 price target suggests 21% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
